Chemotherapy in Advanced Bladder Cancer: Current Status and Future

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2011 Sep 13

PMID 21906310

Citations 33

Authors

Nabil Ismaili

Mounia Amzerin

Aude Flechon

Affiliations

Soon will be listed here.

Abstract

Bladder cancer occurs in the majority of cases in males. It represents the seventh most common cancer and the ninth most common cause of cancer deaths for men. Transitional cell carcinoma is the most predominant histological type. Bladder cancer is highly chemosensitive. In metastatic setting, chemotherapy based on cisplatin should be considered as standard treatment of choice for patients with good performance status (0-1) and good renal function-glomerular filtration rate (GFR) > 60 mL/min. The standard treatment is based on cisplatin chemotherapy regimens type MVAC, HD-MVAC, gemcitabine plus cisplatin (GC) or dose dense GC. In unfit patients, carboplatin based regimes; gemcitabine plus carboplatin or methotrexate plus carboplatin plus vinblastine (MCAVI) are reasonable options. The role of targeted therapies when used alone, or in combination with chemotherapy, or in maintenance, was evaluated; targeting angiogenesis seem to be very promising. The purpose of this literature review is to highlight the role of chemotherapy in the management of advanced transitional cell carcinoma of the bladder.

Citing Articles

DLGAP5 enhances bladder cancer chemoresistance by regulating glycolysis through MYC stabilization.

Deng Z, Zhou F, Li M, Jin W, Yu J, Wang G Theranostics. 2025; 15(6):2375-2392.

PMID: 39990228 PMC: 11840727. DOI: 10.7150/thno.102730.

Hypoalbuminemia and cisplatin-induced acute kidney injury.

Yin W, Huang Y, Zhu Q, Lin X, Piao H, Yu Q Front Pharmacol. 2024; 15:1510477.

PMID: 39723253 PMC: 11668559. DOI: 10.3389/fphar.2024.1510477.

A Novel Approach for Bladder Cancer Treatment: Nanoparticles as a Drug Delivery System.

Zhao X, Qi X, Liu D, Che X, Wu G Int J Nanomedicine. 2024; 19:13461-13483.

PMID: 39713223 PMC: 11662911. DOI: 10.2147/IJN.S498729.

The oncogenic functions of SPARCL1 in bladder cancer.

Li C, Yuan H, Chen J, Shang K, He H J Cell Mol Med. 2024; 28(22):e70196.

PMID: 39548034 PMC: 11567778. DOI: 10.1111/jcmm.70196.

Hyperthermia reduces cancer cell invasion and combats chemoresistance and immune evasion in human bladder cancer.

Tsai T, Hwang T, Chen P, Chen Y, Chou K, Ho C Int J Oncol. 2024; 65(6).

PMID: 39513598 PMC: 11575926. DOI: 10.3892/ijo.2024.5704.

References

Philips G, Halabi S, Sanford B, Bajorin D, Small E . A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Ann Oncol. 2009; 20(6):1074-9. PMC: 2685451. DOI: 10.1093/annonc/mdn749. View

Hussain M, Vaishampayan U, Du W, Redman B, Smith D . Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol. 2001; 19(9):2527-33. DOI: 10.1200/JCO.2001.19.9.2527. View

Edelman M, Meyers F, Miller T, Williams S, Gandour-Edwards R, deVere White R . Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: a well-tolerated regimen with activity independent of p53 mutation. Urology. 2000; 55(4):521-5. DOI: 10.1016/s0090-4295(99)00538-5. View

Meluch A, Greco F, Burris 3rd H, ORourke T, Ortega G, Steis R . Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol. 2001; 19(12):3018-24. DOI: 10.1200/JCO.2001.19.12.3018. View

Jimenez R, Hussain M, Bianco Jr F, Vaishampayan U, Tabazcka P, Sakr W . Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res. 2001; 7(8):2440-7. View

Wulfing C, Machiels J, Richel D, Grimm M, Treiber U, de Groot M . A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer. 2009; 115(13):2881-90. DOI: 10.1002/cncr.24337. View

Bellmunt J, Guillem V, Paz-Ares L, Gonzalez-Larriba J, Carles J, Saenz A . Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol. 2000; 18(18):3247-55. DOI: 10.1200/JCO.2000.18.18.3247. View

Vollmer R, Humphrey P, Swanson P, Wick M, Hudson M . Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2. Cancer. 1998; 82(4):715-23. DOI: 10.1002/(sici)1097-0142(19980215)82:4<715::aid-cncr15>3.0.co;2-0. View

Gallagher D, Milowsky M, Gerst S, Ishill N, Riches J, Regazzi A . Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol. 2010; 28(8):1373-9. DOI: 10.1200/JCO.2009.25.3922. View

10.

Seo Y, Kim S, Kim H, Kim C, Park S, Koh E . Complete response to FOLFOX4 therapy in a patient with advanced urothelial cancer: a case report. J Hematol Oncol. 2010; 3:4. PMC: 2818621. DOI: 10.1186/1756-8722-3-4. View

11.

Gitlitz B, Baker C, Chapman Y, Allen H, Bosserman L, Patel R . A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer. 2003; 98(9):1863-9. DOI: 10.1002/cncr.11726. View

12.

Galsky M, Iasonos A, Mironov S, Scattergood J, Boyle M, Bajorin D . Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function. Cancer. 2007; 109(3):549-55. DOI: 10.1002/cncr.22454. View

13.

Small E, Lew D, Redman B, Petrylak D, Hammond N, Gross H . Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. J Clin Oncol. 2000; 18(13):2537-44. DOI: 10.1200/JCO.2000.18.13.2537. View

14.

Troner M, Birch R, Omura G, Williams S . Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: a Southeastern Cancer Study Group trial. J Urol. 1987; 137(4):660-2. DOI: 10.1016/s0022-5347(17)44167-x. View

15.

Shannon C, Crombie C, Brooks A, Lau H, Drummond M, Gurney H . Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features. Ann Oncol. 2001; 12(7):947-52. DOI: 10.1023/a:1011186104428. View

16.

Hainsworth J, Meluch A, Litchy S, Schnell F, Bearden J, Yost K . Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer. 2005; 103(11):2298-303. DOI: 10.1002/cncr.21078. View

17.

Tu S, Hossan E, Amato R, Kilbourn R, Logothetis C . Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J Urol. 1995; 154(5):1719-22. View

18.

Garcia Del Muro X, Marcuello E, Guma J, Paz-Ares L, Climent M, Carles J . Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer. Br J Cancer. 2002; 86(3):326-30. PMC: 2375206. DOI: 10.1038/sj.bjc.6600121. View

19.

Lonn U, Lonn S, FRIBERG S, Nilsson B, Silfversward C, Stenkvist B . Prognostic value of amplification of c-erb-B2 in bladder carcinoma. Clin Cancer Res. 1995; 1(10):1189-94. View

20.

Xu X, Wang L, Abrams J, Wang G . Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer. J Hematol Oncol. 2011; 4:17. PMC: 3108377. DOI: 10.1186/1756-8722-4-17. View